...
首页> 外文期刊>Current Cancer Drug Targets >Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents
【24h】

Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents

机译:有效和选择性EGFR酪氨酸激酶抑制剂作为抗癌药的合理设计

获取原文
获取原文并翻译 | 示例

摘要

Increasing knowledge of the structure and function of the Epidermal Growth Factor Receptor (EGFR) subfamily of tyrosine kinases, and of their role in the initiation and progression of various cancers has led to the search for inhibitors of signaling molecules that may prove to be important in cancer therapy. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Different approaches have been used to target either the extracellular ligand-binding domain of the EGFR or the intracellular tyrosine kinase region that results in interference with its signaling pathways that modulate cancer-promoting responses. Examples of these include a number of monoclonal antibodies, immunotoxins and ligand-binding cytotoxic agents that target the extracellular ligand binding region of EGFR, and small molecule inhibitors that target the intracellular kinase domain and act by interfering with ATP binding to the receptor. During the past 3 years, significant progress has been made towards the identification of new structural classes of small molecule inhibitors that show high potency and specificity towards EGFR. The search for new small molecules that inhibit kinases has included traditional approaches like the testing of natural products, random screening of chemical libraries, the use of classical structure-activity-relationship studies, and the incorporation of structurebased drug design and combinatorial chemistry techniques. There has been a significant improvement in the development of selective EGFR inhibitors with the use of a structure-based design approach employing a homology model of the EGFR kinase domain. Molecular modeling procedures have been used to generate novel molecules that are complementary in shape and electrostatics to the EGFR kinase domain topography. This review focuses on some examples of the successful use of this method.
机译:对酪氨酸激酶的表皮生长因子受体(EGFR)亚家族的结构和功能及其在各种癌症的发生和发展中的作用的了解不断增加,因此人们正在寻找可能证明是重要的信号分子抑制剂。癌症治疗。 EGFR生物学的复杂性质使EGFR抑制剂在许多癌症治疗领域(包括增殖,血管生成,浸润和转移方面)具有潜在的机会。已经使用不同的方法靶向EGFR的细胞外配体结合结构域或细胞内酪氨酸激酶区域,这导致干扰其调节癌症促进反应的信号传导途径。这些的例子包括许多单克隆抗体,靶向EGFR胞外配体结合区的免疫毒素和结合配体的细胞毒剂,以及靶向细胞内激酶结构域并通过干扰与受体结合的ATP起作用的小分子抑制剂。在过去的三年中,在鉴定对EGFR具有高效力和特异性的小分子抑制剂的新结构类别方面已经取得了重大进展。寻找抑制激酶的新小分子的方法包括传统方法,例如天然产物的测试,化学文库的随机筛选,经典的结构-活性-关系研究的使用,以及基于结构的药物设计和组合化学技术的结合。通过使用基于结构的设计方法,采用EGFR激酶域的同源性模型,选择性EGFR抑制剂的开发有了显着的进步。分子建模程序已用于生成形状和静电与EGFR激酶结构域地形互补的新型分子。本文将重点介绍成功使用此方法的一些示例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号